«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

27卷

期数:

2021年05期

页码:

487-491

栏目:

基础医学

出版日期:

2021-09-10

文章信息/Info

Title:

Protective effects of IL-18 inhibitors on sepsis associated thrombocytopenia in mice

文章编号:

1006-8147(2021)05-0487-05

作者:

李家富¹; 许华²; 王勇强²

（1.天津医科大学一中心临床学院，天津 ³001⁹2；2.天津市第一中心医院重症医学科，天津市急救医学研究所，天津 ³001⁹2）

Author(s):

LI Jia-fu¹; XU Hua²; WANG Yong-qiang²

（1. The First Central Clinical College of Tianjin Medical University，Tianjin 300192，China; 2. Department of Intensive Care Unit，Emergency Medicine Research Institute，Tianjin First Center Hospital，Tianjin 300192，China）

关键词:

IL-18Bp; 脂多糖; 血小板减少; 小鼠

Keywords:

IL-18Bp：lipopolysaccharide; thrombocytopenia; mice

分类号:

R515.3

DOI:

-

文献标志码:

A

摘要:

目的：探究白细胞介素（IL）-18抑制剂 （IL-18Bp）对脓毒症并发血小板减少小鼠的保护作用。方法：将30只C57BL/6雄性小鼠依次编号，按照随机数字表法分为3组：对照组、脂多糖（LPS）注射模型组（LPS组）、LPS加IL-18Bp干预组（LPS/IL-18Bp组）。其中LPS组和LPS/IL-18Bp组给予单次腹腔注射30 mg/kg LPS制备脓毒症并发血小板减少模型，对照组给予等体积生理盐水；LPS/IL-18Bp组在注射LPS后给予单次腹腔注射50 μg/kg IL-18Bp，其余各组给予等体积生理盐水。观察各组72 h生存率，并于LPS注射后24 h时收集血液样本和脾脏组织，全血细胞分析仪检测血小板计数，ELISA法检测各组富血小板血浆中血小板活化标志物sCD40L以及IL-18和IL-6、IL-10、肿瘤坏死因子（TNF）-α的表达情况；HE染色观察并分析各组脾脏的病理变化。结果：LPS/IL-18Bp组各时间点的生存率均高于LPS组（χ2=0.63，P<0.05）；LPS注射后24 h时LPS/IL-18Bp组血小板计数显著高于LPS组（t=8.37，P=0.001）；LPS/IL-18Bp组sCD40L表达量较LPS组低（t=4.34，P=0.012）；LPS/IL-18Bp组小鼠富血小板血浆中IL-18、IL-6、IL-10和TNF-α的表达均较LPS组显著降低（t=8.18、10.95、5.34、10.68，均P＜0.05）；脾脏病理分析显示，LPS/IL-18Bp组脾脏炎症细胞较LPS组明显减少。结论：IL-18Bp能够缓解LPS诱导小鼠血小板减少、血小板活化和炎症反应，并提高LPS诱导血小板减少小鼠模型的生存率，对LPS诱导血小板减少模型小鼠具有一定的保护作用。

Abstract:

Objective: To investigate the protective effect of interleukinc（IL）-18 inhibitor（IL-18Bp） on mice with sepsis complicated with thrombocytopenia（TCP）. Methods: Thirty C57BL/6 male mice were numbered sequentially，according to the random number table method，they were divided into three groups：control group，lipopolysaccharide（LPS） injection model group（LPS group），and IL-18Bp intervention group（LPS/IL-18Bp group）. The model of sepsis mice with thrombocytopenia was prepared by single intraperitoneal injection of 30 mg/kg LPS in the LPS group and the LPS/ IL-18Bp group，and the control group was given constant volume of normal saline. Mice in the LPS/ IL-18Bp group were given a single intraperitoneal injection of 50 μg/kg IL-18Bp after LPS injection，and the other groups were given the same volume of normal saline. The survival rate of mice in each group after 72 hours were observed. Blood samples and spleen tissues were collected 24 hours after LPS injection. The platelet count was measured by a whole blood cell analyzer. The expression of platelet activation marker sCD40L，IL-18 and inflammatory factors such as IL-6，IL-10 and tumor necrosis factor（TNF）-α in platelet-rich plasma was detected by enzyme-linked immunosorbent assay（ELISA）. The pathological changes of spleen in each group were observed and analyzed by hematoxylin-eosin staining（HE）. Results: The survival rate of mice in the IL-18Bp intervention group was higher than that in the LPS group at all time points（χ2=0.63，P<0.05）. At 24 hours after LPS injection，the platelet count of IL-18Bp intervention group was significantly higher than that of LPS group（t=8.37，P=0.001）. The expression of sCD40L in IL-18Bp intervention group was lower than that in LPS group（t=4.34，P=0.012）. The expressions of IL-18，IL-6，IL-10 and TNF-α in platelet-rich plasma of mice in IL-18Bp intervention group were significantly lower than those in LPS group（t=8.18，10.95，5.34，10.68，all P<0.05）. The pathological analysis of spleen showed that the inflammatory cells in the spleen of mice of the IL-18Bp intervention group were significantly reduced compared with the LPS group. Conclusion: IL-18Bp can alleviate thrombocytopenia，platelet activation and inflammation in TCP mice induced by LPS，and improve the survival rate of TCP mice induced by LPS，and has a certain protective effect on the model of TCP mice induced by LPS.

参考文献/References:

[1] VAN DER PIJL E，VAN PUTTEN M，NIKS E，et al. Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice[J]. Neuromuscul Disord，2018，28（5）：427
[2] TUFFERY-GIRAUD S，MIRO J，KOENIG M，et al. Normal and altered pre-mRNA processing in the DMD gene[J]. Hum Genet，2017， 136（9）：1155
[3] GUIRAUD S，AARTSMA-RUS A，VIEIRA N，et al. The pathogenesis and therapy of muscular dystrophies[J]. Annu Rev Genomics Hum Genet，2015，16：281
[4] 卜鑫珏，奚鑫，刘松青，等. 治疗杜兴肌肉萎缩症的新药及其开发[J]. 中国新药杂志，2020，29（2）：165
[5] MATTHEWS E，BRASSINGTON R，KUNTZER T，et al. Corticosteroids for the treatment of Duchenne muscular dystrophy[J]. Cocharne Db Syst Rev，2016（5）：CD003725
[6] PEVERELLI L，TESTOLIN S，VILLA L，et al. Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy[J]. Neurology，2015，85（21）：1886
[7] HEIER C，DAMSKER J，YU Q，et al. VBP15，a novel anti-inflammatory and membrane-stabilizer，improves muscular dystrophy without side effects[J]. EMBO Mol Med，2013，5（10）：1569
[8] LIM K，MARUYAMA R，YOKOTA T. Eteplirsen in the treatment of Duchenne muscular dystrophy[J]. Drug Des Devel Ther，2017，11：533
[9] CIRAK S，ARECHAVALA-GOMEZA V，GUGLIERI M，et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment：an open-label，phase 2，dose-escalation study[J]. Lancet，2011，378（9791）：595
[10] HU Y，WU B，ZILLMER A，et al. Guanine analogues enhance antisense oligonucleotide-induced exon skipping in dystrophin gene in vitro and in vivo[J]. Mol Ther，2010，18（4）：812
[11] KENDALL G，MOKHONOVA E，Moran M，et al. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy[J]. Sci Transl Med，2012，4（164）：164
[12] HAN G，GU B，CAO L，et al. Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice[J]. Nat Commun，2016，7：1098
[13] LIN C，HAN G，NING H，et al. Glycine eenhances satellite cell proliferation，cell transplantation，and oligonucleotide efficacy in dystrophic muscle[J]. Mol Ther，2020，28（5）：1339
[14] CHAWLA J，KVARNBERG D. Hydrosoluble vitamins[J]. Handb Clin Neurol，2014，120：891
[15] RAHIMOV F，KUNKEL L. The cell biology of disease：cellular and molecular mechanisms underlying muscular dystrophy[J]. J Cell Biol，2013，201（4）：499
[16] KLEIN S，PRANTL L，GEIS S，et al. Circulating serum CK level vs. muscle impairment for in situ monitoring burden of disease in mdx-mice[J]. Clin Hemorheol Microcirc，2017，65（4）：327
[17] LEWON M，PETERS C，VAN RY P，et al. Evaluation of the behavioral characteristics of the mdx mouse model of Duchenne muscular dystrophy through operant conditioning procedures[J]. Behav Processes，2017，142：8
[18] STEIN C. Eteplirsen approved for Duchenne muscular dystrophy：the FDA faces a difficult choice[J]. Mol Ther，2016，24（11）：1884
[19] ANWAR S，YOKOTA T. Golodirsen for Duchenne muscular dystrophy[J]. Drugs Today （Barc），2020，56（8）：491
[20] 宁含含，顾犇，韩刚，等. 己糖对杜兴肌肉萎缩症核酸药物Pip5e-PMO跳读活性研究[J]. 天津医科大学学报，2019，25（3）：215
[21] VOLKOV I，PRESS Y，RUDOY I. Vitamin B12 could be a "master key" in the regulation of multiple pathological processes[J]. J Nippon Med Sch，2006，73（2）：65
[22] ERFANPARAST A，Escort M，Tamaddonfard E，et al. Systemic and local peripheral injections of vitamin B12 suppressed orofacial nociception induced by formalin in rats[J]. Drug Res，2014，64（2）：85

相似文献/References:

[1]李新月.脂多糖对牙周膜成纤维细胞IL-8和RANKL基因表达的调节作用[J].天津医科大学学报,2013,19(06):452.
　LI Xin-yue.Regulation of IL-8 and RANKL gene expression by lipopolysaccharide in human periodontal ligament fibroblasts[J].Journal of Tianjin Medical University,2013,19(05):452.
[2]薛 栋,蒋少云*,邓嘉胤,等.牙龈卟啉单胞菌脂多糖对人牙周膜细胞成骨分化能力的影响[J].天津医科大学学报,2015,21(04):299.
　XUE Dong,JIANG Shao-yun,DENG Jia-yin,et al.Effects of Porphyromonas gingivalis lipopolysaccharide on osteogenic differentiation of human periodontal ligament cells[J].Journal of Tianjin Medical University,2015,21(05):299.

备注/Memo

备注/Memo:

基金项目 天津市卫生和计划生育委员会攻关课题（14KG101）；天津市第一中心医院科技基金（院 CM201809）
作者简介 李家富(1993－)，男，硕士在读，研究方向：脓毒症；通信作者：王勇强，E-mail：yongqiangwang1962@sina.com。

常用功能

更新日期/Last Update: 2021-09-01